Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of “Moderate Buy” from Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has earned an average rating of “Moderate Buy” from the twenty-seven research firms that are presently covering the stock, Marketbeat.com reports. Ten equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $792.6522.

REGN has been the subject of a number of recent analyst reports. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $800.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Royal Bank Of Canada lowered their price objective on shares of Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research report on Monday, May 18th. Finally, Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a research report on Monday, May 18th.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $609.94 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The stock has a market cap of $64.48 billion, a PE ratio of 14.86, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25. The stock has a 50-day moving average of $676.81 and a 200-day moving average of $732.16. Regeneron Pharmaceuticals has a one year low of $506.38 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the business posted $8.22 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of REGN. Ellerson Group Inc. ADV boosted its holdings in shares of Regeneron Pharmaceuticals by 49.2% in the 3rd quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock valued at $4,556,000 after purchasing an additional 2,671 shares in the last quarter. Nordea Investment Management AB boosted its holdings in shares of Regeneron Pharmaceuticals by 118.1% in the 4th quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares in the last quarter. TD Asset Management Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 15.9% in the 3rd quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock valued at $210,437,000 after purchasing an additional 51,407 shares in the last quarter. Stevens Capital Management LP acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $792,000. Finally, Mackenzie Financial Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 26.8% in the 3rd quarter. Mackenzie Financial Corp now owns 128,623 shares of the biopharmaceutical company’s stock valued at $72,321,000 after purchasing an additional 27,205 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.